Phase 2 30 items
Trials, agents, guidance
- Trial ALPACAR (zerlasiran phase 2)
- Trial KRAKEN (muvalaplin phase 2)
- Trial ALPACA (lepodisiran phase 2)
- Trial OCEAN(a)-DOSE
- Trial Pelacarsen phase 2 (AKCEA-APO(a)-LRx)
Studies
- OCEAN(a)-DOSE: olpasiran lowers Lp(a) by more than 95 percent in patients with ASCVD (O'Donoghue et al., NEJM 2022)
- Pelacarsen (AKCEA-APO(a)-LRx) lowers Lp(a) by up to 80 percent in patients with cardiovascular disease: the phase 2 trial (Tsimikas et al., NEJM 2020)
- ALPACA: lepodisiran 400 mg lowers Lp(a) by 94 percent from day 60 to 180, and by 95 percent over a year with a second dose (Nissen et al., NEJM 2025)
- KRAKEN: oral muvalaplin lowers Lp(a) by 82 to 86 percent on an intact-particle assay (Nicholls et al., JAMA 2025)
- IONIS-APO(a)Rx and the GalNAc-conjugated APO(a)-LRx: two dose-ranging trials (Viney et al., Lancet 2016)
- ALPACAR: zerlasiran lowers time-averaged Lp(a) by more than 80 percent over 36 weeks in ASCVD (Nissen et al., JAMA 2024)
- After stopping olpasiran, Lp(a) stays 40 to 50 percent below baseline for nearly a year: OCEAN(a)-DOSE extension (O'Donoghue et al., JACC 2024)
- Antisense drug IONIS-APO(a)Rx reveals standard LDL-C tests overestimate true LDL-C by up to 50% in high-Lp(a) patients, a phase 2 trial (J Clin Lipidol 2018)
- Evolocumab cuts Lp(a) by up to 29.5%, a pooled analysis of 4 phase 2 trials and 1359 patients (J Am Coll Cardiol 2014)
- AMG145 (evolocumab) cuts Lp(a) by up to 32% in statin-treated patients, the LAPLACE-TIMI 57 phase 2 trial of 631 patients (Circulation 2013)
- Pelacarsen does not alter platelet reactivity via thromboxane A2 or P2Y12 pathways in 275 patients on aspirin or dual antiplatelet therapy (J Thromb Thrombolysis 2023)
- The OCEAN(a)-DOSE trial enrolls 281 patients to find olpasiran optimal dose ahead of a cardiovascular outcomes trial (Am Heart J 2022)
- Antisense oligonucleotide cuts Lp(a) by 69%, but does not affect fibrinolysis, a placebo-controlled trial of 17 patients (J Lipid Res 2019)
- Olezarsen reduces Lp(a)-associated triglycerides and cholesterol by 56% to 70% without lowering plasma Lp(a) (JACC Basic Transl Sci 2026)
- lepodisiran reduces oxidized phospholipids on Lp(a) by up to 94 percent in a phase 2 trial (J Am Coll Cardiol 2026)
- Antisense drug IONIS-APO(a)-LRX cuts Lp(a) by 90% in a phase 2 trial, a review of Lp(a) and atherosclerotic disease (Cardiovasc Drugs Ther 2019)
- Antisense drug AKCEA-APO(a)-LRx cuts Lp(a) by up to 80% as a phase 3 outcomes trial is planned, a review of antisense oligonucleotides for Lp(a) (Curr Atheroscler Rep 2019)
Video and podcasts
AHA 2024: KRAKEN, oral muvalaplin lowers Lp(a) by up to 85 percent (Stephen Nicholls)
AHA 2024: ALPACAR, zerlasiran in adults with elevated Lp(a) at high ASCVD risk (Steven Nissen)
